| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Dysplasia | 17 | 2023 | 219 | 5.930 |
Why?
|
| Papillomavirus Infections | 22 | 2023 | 980 | 4.200 |
Why?
|
| Uterine Cervical Neoplasms | 20 | 2023 | 1833 | 3.070 |
Why?
|
| Vaginal Smears | 13 | 2023 | 192 | 2.670 |
Why?
|
| Alphapapillomavirus | 6 | 2022 | 171 | 2.460 |
Why?
|
| Biopsy, Fine-Needle | 15 | 2022 | 690 | 2.070 |
Why?
|
| Papanicolaou Test | 9 | 2021 | 141 | 1.880 |
Why?
|
| Papillomaviridae | 12 | 2023 | 624 | 1.840 |
Why?
|
| Human papillomavirus 16 | 9 | 2023 | 256 | 1.600 |
Why?
|
| Human papillomavirus 18 | 4 | 2023 | 43 | 1.170 |
Why?
|
| Vaginal Neoplasms | 3 | 2015 | 152 | 0.950 |
Why?
|
| Image-Guided Biopsy | 2 | 2020 | 327 | 0.940 |
Why?
|
| In Situ Hybridization | 4 | 2018 | 1037 | 0.910 |
Why?
|
| Cervix Uteri | 5 | 2021 | 253 | 0.860 |
Why?
|
| DNA, Viral | 10 | 2015 | 694 | 0.830 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 2 | 2019 | 15 | 0.780 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2013 | 476 | 0.780 |
Why?
|
| Genital Neoplasms, Female | 2 | 2023 | 735 | 0.690 |
Why?
|
| Immunohistochemistry | 12 | 2019 | 7548 | 0.680 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 134 | 0.680 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2022 | 5437 | 0.650 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2020 | 123 | 0.640 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 1217 | 0.600 |
Why?
|
| Carcinoma in Situ | 2 | 2022 | 487 | 0.560 |
Why?
|
| Head and Neck Neoplasms | 3 | 2022 | 3976 | 0.510 |
Why?
|
| Genotype | 9 | 2021 | 4109 | 0.500 |
Why?
|
| Precancerous Conditions | 2 | 2012 | 1058 | 0.500 |
Why?
|
| Biopsy, Needle | 7 | 2012 | 1363 | 0.490 |
Why?
|
| Lung Neoplasms | 8 | 2020 | 11538 | 0.490 |
Why?
|
| Early Detection of Cancer | 6 | 2023 | 1258 | 0.480 |
Why?
|
| Middle Aged | 41 | 2023 | 86204 | 0.470 |
Why?
|
| Blastomycosis | 3 | 2002 | 17 | 0.460 |
Why?
|
| Fallopian Tube Diseases | 1 | 2013 | 18 | 0.460 |
Why?
|
| Mass Screening | 1 | 2021 | 1509 | 0.430 |
Why?
|
| Mullerian Ducts | 1 | 2013 | 76 | 0.430 |
Why?
|
| Aged | 35 | 2021 | 70117 | 0.420 |
Why?
|
| Adult | 35 | 2021 | 77950 | 0.410 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2013 | 486 | 0.410 |
Why?
|
| Female | 51 | 2023 | 141928 | 0.400 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2011 | 28 | 0.400 |
Why?
|
| Endometriosis | 1 | 2013 | 214 | 0.370 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2009 | 17 | 0.360 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2021 | 1105 | 0.360 |
Why?
|
| Virology | 1 | 2009 | 32 | 0.360 |
Why?
|
| Predictive Value of Tests | 7 | 2014 | 4892 | 0.350 |
Why?
|
| Triage | 1 | 2011 | 252 | 0.340 |
Why?
|
| ErbB Receptors | 4 | 2020 | 2295 | 0.340 |
Why?
|
| Humans | 63 | 2023 | 261506 | 0.340 |
Why?
|
| Retrospective Studies | 22 | 2023 | 37905 | 0.330 |
Why?
|
| Thyroid Neoplasms | 3 | 2020 | 1866 | 0.320 |
Why?
|
| Biomarkers, Tumor | 11 | 2020 | 10331 | 0.320 |
Why?
|
| Penile Neoplasms | 2 | 2021 | 161 | 0.310 |
Why?
|
| Breast Neoplasms, Male | 1 | 2009 | 229 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2020 | 419 | 0.300 |
Why?
|
| ras Proteins | 1 | 2011 | 770 | 0.290 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2011 | 406 | 0.280 |
Why?
|
| Endometrial Neoplasms | 2 | 2013 | 1341 | 0.280 |
Why?
|
| Neoplasm Proteins | 3 | 2015 | 3230 | 0.270 |
Why?
|
| Viral Load | 1 | 2006 | 493 | 0.250 |
Why?
|
| Sensitivity and Specificity | 3 | 2021 | 4971 | 0.240 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 7789 | 0.240 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 1399 | 0.230 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 14889 | 0.230 |
Why?
|
| Tumor Virus Infections | 1 | 2004 | 224 | 0.230 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 29902 | 0.230 |
Why?
|
| Lung Diseases, Fungal | 2 | 2001 | 124 | 0.230 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 5319 | 0.230 |
Why?
|
| Young Adult | 8 | 2020 | 21445 | 0.220 |
Why?
|
| Anus Diseases | 1 | 2022 | 29 | 0.220 |
Why?
|
| Blastomyces | 2 | 2001 | 8 | 0.210 |
Why?
|
| Paired Box Transcription Factors | 2 | 2013 | 134 | 0.210 |
Why?
|
| Smoking | 1 | 2011 | 2440 | 0.210 |
Why?
|
| Diagnosis, Differential | 7 | 2020 | 4744 | 0.210 |
Why?
|
| Somatostatinoma | 1 | 2001 | 2 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 2488 | 0.200 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 289 | 0.200 |
Why?
|
| Biopsy | 4 | 2013 | 3443 | 0.200 |
Why?
|
| Specimen Handling | 2 | 2013 | 299 | 0.200 |
Why?
|
| Data Accuracy | 1 | 2021 | 54 | 0.190 |
Why?
|
| Gene Amplification | 2 | 2020 | 731 | 0.190 |
Why?
|
| Magnesium Deficiency | 1 | 2020 | 21 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 10035 | 0.190 |
Why?
|
| Vulvar Neoplasms | 1 | 2022 | 236 | 0.190 |
Why?
|
| Duodenal Neoplasms | 1 | 2001 | 138 | 0.190 |
Why?
|
| Tissue Fixation | 2 | 2018 | 136 | 0.190 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2001 | 145 | 0.180 |
Why?
|
| Ampulla of Vater | 1 | 2001 | 155 | 0.180 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 509 | 0.180 |
Why?
|
| Ovarian Neoplasms | 2 | 2013 | 4638 | 0.180 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2020 | 37 | 0.180 |
Why?
|
| Human Papillomavirus DNA Tests | 2 | 2017 | 18 | 0.180 |
Why?
|
| Immunoenzyme Techniques | 5 | 2015 | 1165 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 8873 | 0.180 |
Why?
|
| Male | 26 | 2021 | 123000 | 0.180 |
Why?
|
| Reproducibility of Results | 6 | 2019 | 6009 | 0.170 |
Why?
|
| Ultrasonography | 4 | 2020 | 1863 | 0.170 |
Why?
|
| Carcinoma | 1 | 2011 | 2578 | 0.170 |
Why?
|
| Cohort Studies | 5 | 2020 | 9244 | 0.170 |
Why?
|
| Adolescent | 12 | 2020 | 31252 | 0.170 |
Why?
|
| Myositis | 1 | 1999 | 79 | 0.170 |
Why?
|
| Sarcoidosis | 1 | 1999 | 112 | 0.160 |
Why?
|
| Anus Neoplasms | 1 | 2022 | 411 | 0.160 |
Why?
|
| DNA Probes, HPV | 2 | 2008 | 15 | 0.160 |
Why?
|
| Formaldehyde | 1 | 2018 | 114 | 0.160 |
Why?
|
| Lung | 3 | 2020 | 3151 | 0.160 |
Why?
|
| Neoplasm Grading | 3 | 2019 | 1742 | 0.160 |
Why?
|
| Anal Canal | 1 | 2019 | 238 | 0.160 |
Why?
|
| Cytodiagnosis | 3 | 2014 | 220 | 0.160 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 226 | 0.160 |
Why?
|
| Vagina | 2 | 2022 | 317 | 0.160 |
Why?
|
| Atypical Squamous Cells of the Cervix | 1 | 2017 | 5 | 0.150 |
Why?
|
| Databases, Factual | 2 | 2017 | 2218 | 0.150 |
Why?
|
| Prognosis | 9 | 2020 | 21713 | 0.150 |
Why?
|
| Scalp | 1 | 1999 | 156 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 5539 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2017 | 6869 | 0.150 |
Why?
|
| Angiomyolipoma | 1 | 2017 | 31 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 408 | 0.140 |
Why?
|
| PAX8 Transcription Factor | 2 | 2013 | 55 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 3203 | 0.140 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1999 | 272 | 0.140 |
Why?
|
| Mutation | 4 | 2020 | 15179 | 0.140 |
Why?
|
| Age Factors | 3 | 2019 | 5377 | 0.130 |
Why?
|
| Mammaglobin A | 1 | 2015 | 14 | 0.130 |
Why?
|
| Histoplasmosis | 1 | 2015 | 74 | 0.130 |
Why?
|
| Adrenal Gland Diseases | 1 | 2015 | 72 | 0.130 |
Why?
|
| SOXE Transcription Factors | 1 | 2014 | 29 | 0.120 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2014 | 42 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2020 | 2232 | 0.120 |
Why?
|
| SOXC Transcription Factors | 1 | 2014 | 53 | 0.120 |
Why?
|
| GATA3 Transcription Factor | 1 | 2015 | 146 | 0.120 |
Why?
|
| Thyroidectomy | 2 | 2020 | 486 | 0.120 |
Why?
|
| Signal Transduction | 2 | 2011 | 11965 | 0.120 |
Why?
|
| Receptors, Estrogen | 2 | 2012 | 2086 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2019 | 1143 | 0.120 |
Why?
|
| Skin Neoplasms | 3 | 2014 | 4654 | 0.120 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 716 | 0.120 |
Why?
|
| Staining and Labeling | 2 | 2015 | 429 | 0.120 |
Why?
|
| Peritoneal Lavage | 1 | 2013 | 21 | 0.120 |
Why?
|
| NF-kappa B | 2 | 2011 | 1549 | 0.110 |
Why?
|
| Candidiasis | 1 | 2015 | 262 | 0.110 |
Why?
|
| Cold Ischemia | 1 | 2012 | 22 | 0.110 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2012 | 45 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 1999 | 1270 | 0.100 |
Why?
|
| Ascitic Fluid | 1 | 2012 | 76 | 0.100 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2013 | 170 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 1946 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2020 | 1589 | 0.100 |
Why?
|
| WT1 Proteins | 1 | 2012 | 106 | 0.100 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2011 | 97 | 0.100 |
Why?
|
| Glycoproteins | 1 | 2015 | 747 | 0.100 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2012 | 132 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2012 | 756 | 0.100 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2011 | 70 | 0.100 |
Why?
|
| Neck Dissection | 1 | 2012 | 290 | 0.100 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1998 | 962 | 0.100 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5112 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2011 | 53 | 0.100 |
Why?
|
| Cytoplasm | 1 | 2013 | 652 | 0.100 |
Why?
|
| Cytological Techniques | 1 | 2011 | 74 | 0.100 |
Why?
|
| Codon | 1 | 2011 | 241 | 0.090 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2011 | 211 | 0.090 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2011 | 133 | 0.090 |
Why?
|
| Receptors, Nicotinic | 1 | 2011 | 190 | 0.090 |
Why?
|
| Body Fluids | 1 | 2011 | 125 | 0.090 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2011 | 269 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2019 | 5270 | 0.090 |
Why?
|
| Keratin-6 | 1 | 2009 | 39 | 0.090 |
Why?
|
| Keratin-5 | 1 | 2009 | 57 | 0.090 |
Why?
|
| Loss of Heterozygosity | 1 | 2011 | 602 | 0.090 |
Why?
|
| Bovine papillomavirus 1 | 1 | 2008 | 8 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2008 | 311 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 429 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 383 | 0.080 |
Why?
|
| Thyroid Gland | 1 | 2011 | 355 | 0.080 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2014 | 713 | 0.080 |
Why?
|
| Kidney Neoplasms | 2 | 2017 | 3022 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2008 | 187 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 3981 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2012 | 2316 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2013 | 1620 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2014 | 895 | 0.080 |
Why?
|
| Exons | 1 | 2011 | 1328 | 0.070 |
Why?
|
| Algorithms | 1 | 2018 | 3890 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 4314 | 0.070 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2010 | 323 | 0.070 |
Why?
|
| Immunocompromised Host | 2 | 2002 | 698 | 0.070 |
Why?
|
| Adamantinoma | 1 | 2006 | 7 | 0.070 |
Why?
|
| Adrenal Cortex | 1 | 2006 | 35 | 0.070 |
Why?
|
| Virus Integration | 1 | 2006 | 76 | 0.070 |
Why?
|
| Sex Factors | 1 | 2012 | 2139 | 0.070 |
Why?
|
| RNA Splicing | 1 | 2008 | 370 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2015 | 2022 | 0.070 |
Why?
|
| Mammography | 1 | 2012 | 1010 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 7551 | 0.070 |
Why?
|
| Thoracic Diseases | 1 | 2006 | 31 | 0.070 |
Why?
|
| Tibia | 1 | 2006 | 131 | 0.070 |
Why?
|
| Mississippi | 2 | 2002 | 26 | 0.070 |
Why?
|
| Lymph Nodes | 2 | 2014 | 2967 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1998 | 2341 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2012 | 1216 | 0.070 |
Why?
|
| Breast | 1 | 2012 | 1344 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 4757 | 0.060 |
Why?
|
| Virus Replication | 1 | 2008 | 709 | 0.060 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2015 | 1215 | 0.060 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 2283 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2005 | 275 | 0.060 |
Why?
|
| Thorax | 1 | 2006 | 213 | 0.060 |
Why?
|
| Surgical Flaps | 2 | 2001 | 927 | 0.060 |
Why?
|
| Lymphoma | 1 | 2013 | 1467 | 0.060 |
Why?
|
| Epithelial Cells | 3 | 2008 | 1818 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 1331 | 0.060 |
Why?
|
| Melanoma | 2 | 2014 | 5317 | 0.060 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2006 | 172 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 3639 | 0.060 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2006 | 223 | 0.060 |
Why?
|
| Fibronectins | 1 | 2004 | 197 | 0.060 |
Why?
|
| Survival Rate | 3 | 2020 | 12221 | 0.060 |
Why?
|
| Prevalence | 2 | 2022 | 3260 | 0.060 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 2138 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 2008 | 984 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 5767 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 2 | 2001 | 345 | 0.050 |
Why?
|
| Breast Neoplasms | 3 | 2012 | 15694 | 0.050 |
Why?
|
| Duodenoscopy | 1 | 2001 | 18 | 0.050 |
Why?
|
| Ureteral Diseases | 1 | 2001 | 16 | 0.050 |
Why?
|
| Mouthwashes | 1 | 2021 | 41 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2004 | 837 | 0.050 |
Why?
|
| Bone Diseases, Infectious | 1 | 2000 | 12 | 0.050 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2000 | 19 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 13658 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2001 | 600 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 197 | 0.050 |
Why?
|
| Lymphokines | 1 | 2001 | 272 | 0.050 |
Why?
|
| Veins | 1 | 2001 | 157 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 4557 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2001 | 208 | 0.040 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2002 | 247 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2009 | 2518 | 0.040 |
Why?
|
| Calcitonin | 1 | 2020 | 186 | 0.040 |
Why?
|
| Ureter | 1 | 2001 | 209 | 0.040 |
Why?
|
| Keratinocytes | 2 | 2011 | 241 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2004 | 854 | 0.040 |
Why?
|
| Genitalia, Female | 1 | 2019 | 68 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 3552 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 4821 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2020 | 829 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 823 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2011 | 2947 | 0.040 |
Why?
|
| Graft Survival | 1 | 2001 | 1062 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 5159 | 0.040 |
Why?
|
| RNA, Viral | 2 | 2010 | 671 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2019 | 375 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 1823 | 0.030 |
Why?
|
| Pneumonia | 1 | 2002 | 751 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1945 | 0.030 |
Why?
|
| MART-1 Antigen | 1 | 2014 | 105 | 0.030 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2014 | 88 | 0.030 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2014 | 82 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 833 | 0.030 |
Why?
|
| United States | 1 | 2011 | 15433 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 2576 | 0.030 |
Why?
|
| Cancer Survivors | 1 | 2020 | 650 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2020 | 1996 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2015 | 244 | 0.030 |
Why?
|
| Cisplatin | 1 | 2020 | 2432 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2012 | 64 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2001 | 2063 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 2803 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2004 | 2326 | 0.030 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2010 | 112 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2014 | 1681 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 1301 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 1226 | 0.020 |
Why?
|
| Pregnancy | 1 | 2002 | 7573 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 672 | 0.020 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2008 | 88 | 0.020 |
Why?
|
| Contrast Media | 1 | 2015 | 1472 | 0.020 |
Why?
|
| RNA Splice Sites | 1 | 2008 | 111 | 0.020 |
Why?
|
| Rats | 3 | 2001 | 6086 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 1972 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 3033 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 1643 | 0.020 |
Why?
|
| Disease Progression | 2 | 2010 | 6682 | 0.020 |
Why?
|
| Child | 4 | 2017 | 29154 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5178 | 0.020 |
Why?
|
| Nuclear Envelope | 1 | 2006 | 39 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 2173 | 0.020 |
Why?
|
| Cell Shape | 1 | 2006 | 128 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 12873 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 2084 | 0.020 |
Why?
|
| Telomerase | 1 | 2008 | 525 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 2450 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2012 | 929 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2008 | 1471 | 0.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2004 | 155 | 0.010 |
Why?
|
| Thoracic Neoplasms | 1 | 2006 | 337 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2004 | 575 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2004 | 376 | 0.010 |
Why?
|
| Polypropylenes | 1 | 2001 | 25 | 0.010 |
Why?
|
| Radiography | 1 | 2006 | 1904 | 0.010 |
Why?
|
| Silicones | 1 | 2001 | 54 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 17523 | 0.010 |
Why?
|
| Foreign-Body Reaction | 1 | 2001 | 27 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2004 | 554 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 212 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2004 | 825 | 0.010 |
Why?
|
| Rectus Abdominis | 1 | 2001 | 100 | 0.010 |
Why?
|
| Necrosis | 1 | 2001 | 580 | 0.010 |
Why?
|
| Random Allocation | 1 | 2001 | 703 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2000 | 495 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2001 | 371 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2004 | 1442 | 0.010 |
Why?
|
| Age Distribution | 1 | 2000 | 698 | 0.010 |
Why?
|
| Models, Animal | 1 | 2001 | 664 | 0.010 |
Why?
|
| Microsurgery | 1 | 2001 | 244 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 4844 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 6150 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 15862 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 2307 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2001 | 891 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 12926 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2001 | 1914 | 0.010 |
Why?
|
| Neoplasms | 1 | 2002 | 15193 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2001 | 1533 | 0.010 |
Why?
|
| Stents | 1 | 2001 | 1096 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2004 | 2669 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 14551 | 0.010 |
Why?
|
| Animals | 3 | 2001 | 59536 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 7702 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 14289 | 0.000 |
Why?
|
| Infant | 1 | 2000 | 13310 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2000 | 16273 | 0.000 |
Why?
|